Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
was going to lay low too, but bought another 20,000 on the dips.
looks like I'll be doing the same thru Fri
more progress = more shares for me in coming days.
Looks like they picked 150 to 1 is they expect the pps to halve so by the time the Ed takes place, the pps will be at $4, still above limit for uplist.
Another pr tomorrow to pop the pps
Any chance the ticker will be fixed?
nice to hear from Dr. Rubenfeld in the Chairman's blog
News out S-3
Small buy at close will green this thing
Not the same,
also, case was dismissed, read end
News out
Many orphan drug in Europe
Check LinkedIn, C Ichim has new position/title
I saw it @ an hour after closing
http://www.pharmacychoice.com/news/article.cfm?Article_ID=1360614
4/22/15 - Regen BioPharma Inc. Announces Small Molecule Drug Discovery Milestones at the American Association for Cancer Research's 2015 Annual Meeting
By a News Reporter-Staff News Editor at Biotech Week Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced the acceptance of its abstract "Discovery of retinoic acids as low affinity inhibitors of the leukemia stem cell target NR2F6" at the American Association for Cancer Research Annual Meeting taking place April 18-22, 2015 in Philadelphia, Pennsylvania.
Christine Ichim, PhD, first author of the abstract and Director of Molecular Therapeutics for Regen BioPharma Inc., will be presenting major milestones in the drug discovery process for small molecule inhibitors of the cancer stem cell gene NR2F6. Cancer stem cells are a novel and coveted therapeutic target in cancer research because they represent the cancer cells that are immortal.
Most cancer cells do not divide or can only divide a limited number of times. On the other hand, cancer stem cells can divide an unlimited number of times making them immortal. While conventional chemotherapy kills the most populous cancer cells, cancer stem cells are often resistant to cancer therapy. The resistance of cancer stem cells to conventional cancer therapy is believed to be the main reason for disease relapse and drug resistance.
Regen BioPharma has recently acquired intellectual property to the cancer stem cell gene NR2F6 and began developing drugs against this therapeutic target from researchers at the University of Toronto.
Regen BioPharma will be announcing at the American Association for Cancer Research Annual Meeting attainment of significant milestones in the drug discovery process, specifically assay development and hit identification. Discussed in the presentation will be the proprietary experimental system that was used to identify small molecules that bind to the active site of the NR2F6 gene product. NR2F6 encodes a nuclear receptor. It is known that this family of drug targets contain an active site called the ligand binding domain. This portion of the protein is the "on-off" switch of its activity. Regen BioPharma has devised a method of zeroing in on this part of the protein, which allows for screening of drugs that selectively that bind to, and turn off the switch. Using this method, existing compounds have been tested for binding as a method of validating the system before novel compounds can be tested for efficacy.
Using this technique, researches showed that retinoic acid was able to activate the assay at supra-physiological concentrations, acting as a "hit". "The role of retinoids as agents of differentiation in embryology, stem cell biology and the maturation of blood cells has been well established. That retinoic acid can bind to our gene, albeit at super-physiological concentrations, is exciting because it validates our initial observation that our target gene functions to inhibit differentiation and to maintain cancer cells in a stem cell state. It validates the hypothesis that by turning off our gene using a small molecule like retinoic acid, we can target specifically the cancer stem cells to mature," said Dr. Christine Ichim.
"The in vitro validation of the critical role of NR2F6 in cancer stem cell maintenance using shRNA, combined with the in vivo validation that NR2F6 transfection causes cancer, strongly convinces us of the therapeutic relevance of our target. The results which will be disclosed at the AACR meeting are the first step in development of small molecule drugs addressing the problem of cancer stem cells," said Thomas Ichim, PhD, Chief Scientific Officer of Regen BioPharma (see also Stem Cells).
Keywords for this news article include: Cancer, Therapy, Oncology, Stem Cell Research.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2015, NewsRx LLC
(c) 2015 NewsRx LLC
possibly 2
1 from the conference
1 regarding a ticker symbol for the free shares
Could u copy and post, when I opened your link I got a malware warning
New optimistic tweet from GC
These three like what RGBP has
buying time
Jason n tweeted a correction, instead of 82 shareholders there r over 10,000
La Jolla
Let's see an EOD jump to .38
News out, see link above
.065, ....right
I smell a ticker symbol on the new shares coming very soon
About to unload a block, be back in a month
glta
That maters alot being that the market is closed today
So now Gerald is a genius?
you forgot we got free shares 2 times
If this was done to make extra money, then the writing is on the wall that within 6 months, big news will hit. Mark your calendar at the 6 month mark as insurance, but by then you'll be on the beach getting an oil rubdown by twins.
Also, the pps is so cheap, people buy 10 to 20 million shares. When price goes up, it gets played too much. One person selling 20 million shares is ridiculous. Realistically, there won't be as much profits taken because of the cheapness of share price and the pennystock flippers. It feels good owning millions of shares, but its off balance with a healthy portfolio.
Same here, sold all BMSN and ENTB
Gerald tweeted last night
Don't sweat over the small stuff
Biz, they are free shares
Called icing on cake
Worry? Lol
Took the wind outta the skippers sail
Good to see progress
RGBP gets acess to the main lab and equipment; leased space is an office/lab.
See below:
1. Scope of Service:
HBRI will provide a variety of professional, scientific and technical services for the proper conduct of research by TENANT.
The relationship between HBRI and TENANT established by this Agreement is that of Landlord and Tenant and nothing contained in this Agreement shall be construed to (i) give either party the power to direct or control the day-to-day activities of the other, (ii) constitute the parties as partners, joint venturers, co-owners or otherwise as participants in a joint or common undertaking, or (iii) allow a party to create or assume any obligation on behalf of the other party for any purpose whatsoever. Accordingly, this Agreement does not entitle TENANT or its employees to any of the rights or benefits accorded HBRI’s employees and does not entitle HBRI or its employees to any of the rights or benefits accorded TENANT’s employees.
HBRI will provide equipment for usage of TENANT personnel and provide proper orientation for safe usage of such equipment. Use of equipment shall be on a priority basis with HBRI research given highest priority. Service for the following equipment includes:
Minus 80 and Minus 20 Freezers & Refrigerators
Balances Chemical Storage and Safety
Autoclave Deionized Water
Milli Q System (ultra pure water) Shipping/ Receiving Room
Benchtop Centrifuge Analytical room UV-Vis Spectrometer
Dark Room (no film) pH Meter
*One cell hood and incubator circulating water bath Centrifuges
*PCR Machine (s) Microwave
*priority given to HBRI
SEE BOLD
DOCUMENTATION OF SAFE ALB PREACTICES
Premises, Rent, and Terms
HBRI shall sublease to CC approximately 199.5 square feet of HBRI leased premises at 5310 Eastgate Mall, San Diego, CA 92121, as depicted in Appendix A attached hereto and incorporated herein (including lab space, hood space and PCR hood), on the terms and conditions set forth in this Agreement. The term of the sublease shall be from March 9, 2015 to September 8, 2015 (a period of 6 months) and will automatically renew thereafter for the same 6 month term unless written notice is received within 60 days prior to renewal. HBRI shall review the sublease agreement periodically and at least annually and have the right to modestly change the terms for good reason; including but not limited to an increase in scope, space, personnel, and usage by CC. An annual cost of living increase of 5% will be implemented each year. Either party may terminate this Agreement upon giving the other party ninety days' written notice.
CC shall pay HBRI $400 on the 1st day of each calendar month of the term. A refundable deposit of $4000 will be due before taking possession of the lab space and shall be refunded to CC no less than thirty days upon the termination of this Agreement provided that CC has substantially complied with its obligations hereunder. Total monthly fees are due by the 1st (first) of each month, regardless of whether or not an invoice is received. If payment is not received by the 10th (tenth) of each month a late fee of $25 will be assessed and the unpaid balance will begin to accrue interest at 10.0% APR compounded monthly from the original due date (the first of the month) until the entire amount owed is paid. HBRI reserves the right to review the payment for services and request additional reasonable reimbursement for reasonable additional costs for time and materials if the payment for service is less than the amount of service provided.
In consideration of the rent payable under this Agreement, CC shall receive use of the premises described above and the privileges and services described herein in conformance with the signed Research Agreement (Appendix E). The Research Agreement is an inextricable portion of this Agreement. CC shall be entitled to the benefit of services and utilities received by HBRI as part of its lease to the subleased premises, including electricity, heating, and janitorial services, and shall further be entitled to use of HBRI washroom/sterilizing facilities, prep room, and mutually agreed equipment and facilities, as listed in Appendix B. HBRI personnel who operate and maintain such equipment and services shall provide reasonable assistance to CC in connection with such use. CC shall provide for their company’s own phone, fax, internet, and printing/copying services and installation.
Any services, materials, and time above and beyond the standard performance of this agreement will be charged separately by HBRI at an hourly rate of $50/hr.
CC shall adhere to all statutory, regulatory, permitting and other San Diego County, State and Federal legal requirements with respect to its activities, and to safe laboratory practices, including without limitation all HBRI procedures concerning chemical, radioisotope, biohazards, and safety regulations. HBRI shall provide CC with copies of HBRI procedures manuals that relate to its facility and health and safety procedures, with which CC shall comply.
Each party shall defend, indemnify, and hold the other harmless from any and all claims, losses, damages, liabilities, and causes of action, including without limitation the payment of reasonable attorneys’ fees and expert witnesses’ fees, which such party may incur in connection with any act or omission by the other party in performance of this Agreement or the other party’s use of the subleased premises. In the case of any disagreement that results in legal action, the prevailing Party shall have legal fees paid by the non-prevailing party.
CC shall not be entitled to use of HBRI mail, fax, and general administration.
This sublease is not transferable and shall not be further subleased.
2 weeks till next conference
this is getting ugly, and looks to be in need of emergency plastic surgery
RGBP now has IND experience, they know the process, can submit with added info that may defer future FDA questions, and ....THEY HAVE FDA CONTACTS
Planning for A lab would have been discussed many months ago, probably with ichim as part of the company plan and part of the draw to get him and eventually his sister here